We are live on ! Find out more
BCM

Bridgeway Capital Management Portfolio holdings

AUM $4.97B
1-Year Est. Return 44.96%
This Fund
S&P 500
This Quarter Est. Return
+7.63%
1 Year Est. Return
+44.96%
3 Year Est. Return
+114.45%
5 Year Est. Return
+175.29%
10 Year Est. Return
+704.01%
AUM
$4.77B
AUM Growth
+$83.3M
Cap. Flow
-$75.7M
Cap. Flow %
-1.59%
Top 10 Hldgs %
8.04%
Holding
1,297
New
101
Increased
425
Reduced
422
Closed
77

Top Buys

Rank Stock Value
1
PTEN icon
Patterson-UTI
PTEN
+$16M
2
CNXC icon
Concentrix
CNXC
+$14M
3
BUR icon
Burford Capital
BUR
+$12.4M
4
XPRO icon
Expro Ltd
XPRO
+$12.4M
5
PRGO icon
Perrigo
PRGO
+$11M

Sector Composition

Rank Sector Weight
1 Financials 28.75%
2 Consumer Discretionary 13.52%
3 Technology 11.88%
4 Industrials 10.57%
5 Energy 9.97%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
LYEL icon
801
Lyell Immunopharma
LYEL
$360M
$554K 0.01%
18,000
ALMS
802
Alumis Inc
ALMS
$3.52B
$554K 0.01%
56,728
-17,000
-23% -$119K
OOMA icon
803
Ooma
OOMA
$604M
$552K 0.01%
+47,100
New +$537K
CIX icon
804
Comp X International
CIX
$371M
$551K 0.01%
23,667
+421
+2% +$9.53K
TENX icon
805
Tenax Therapeutics
TENX
$503M
$547K 0.01%
+44,900
New +$391K
GOSS icon
806
Gossamer Bio
GOSS
$87M
$546K 0.01%
176,000
-159,900
-48% -$456K
LNKB
807
DELISTED
LINKBANCORP
LNKB
$545K 0.01%
66,000
ISSC icon
808
Innovative Solutions & Support
ISSC
$361M
$540K 0.01%
28,500
RIGL icon
809
Rigel Pharmaceuticals
RIGL
$750M
$536K 0.01%
12,520
-9,950
-44% -$375K
PMVP icon
810
PMV Pharmaceuticals
PMVP
$63.5M
$536K 0.01%
428,853
+108,200
+34% +$145K
FTK icon
811
Flotek Industries
FTK
$1.28B
$533K 0.01%
30,925
-30,870
-50% -$490K
AVIR icon
812
Atea Pharmaceuticals
AVIR
$420M
$530K 0.01%
148,400
+5,300
+4% +$16.8K
WHWK
813
Whitehawk Therapeutics
WHWK
$235M
$521K 0.01%
215,284
PKE icon
814
Park Aerospace
PKE
$819M
$514K 0.01%
24,100
STXS icon
815
Stereotaxis
STXS
$141M
$509K 0.01%
221,475
+80,075
+57% +$213K
NATR icon
816
Nature's Sunshine
NATR
$288M
$508K 0.01%
+23,525
New +$431K
LFCR icon
817
Lifecore Biomedical
LFCR
$190M
$506K 0.01%
61,800
SMRT icon
818
SmartRent
SMRT
$272M
$505K 0.01%
250,000
+50,000
+25% +$81.9K
RFIL icon
819
RF Industries
RFIL
$139M
$501K 0.01%
86,696
+20,020
+30% +$139K
EAF icon
820
GrafTech
EAF
$212M
$499K 0.01%
32,200
+2,800
+10% +$42.6K
RAIL icon
821
FreightCar America
RAIL
$260M
$499K 0.01%
45,100
-38,000
-46% -$349K
RAPT
822
DELISTED
RAPT Therapeutics
RAPT
$487K 0.01%
14,375
-6,250
-30% -$194K
TLSI icon
823
TriSalus Life Sciences
TLSI
$345M
$485K 0.01%
69,500
KPTI icon
824
Karyopharm Therapeutics
KPTI
$48M
$485K 0.01%
65,873
+31,000
+89% +$190K
INV
825
Innventure Inc
INV
$289M
$484K 0.01%
115,815
+55,815
+93% +$234K

Similar funds

Bridgeway Capital Management's Q4 2025 Portfolio in Review

As of Q4 2025, Bridgeway Capital Management held 1,297 positions worth $4.77B, up 1.8% from $4.69B the previous quarter. Its ten largest holdings account for 8% of the portfolio.

Bridgeway Capital Management's Q4 2025 filing shows 101 new, 425 increased, 422 reduced and 77 closed positions. Its largest new stake was Patterson-UTI: 2,679,554 shares worth $16.4M. The largest sale was Warrior Met Coal, an estimated $23M.

By sector, the portfolio is most concentrated in Financials at 29% of assets, up from 27% a quarter earlier, followed by Consumer Discretionary and Technology.

  • Bridgeway Capital Management's largest Q4 2025 buy was Patterson-UTI: 2,679,554 shares worth $16.4M.
  • Bridgeway Capital Management added most to Trustmark in Q4 2025, an estimated $9.24M increase.
  • Bridgeway Capital Management's biggest Q4 2025 reduction was Warrior Met Coal, cutting an estimated $23M.
  • Bridgeway Capital Management fully exited Premier in Q4 2025, selling an estimated $19.3M.
  • Bridgeway Capital Management's ten largest holdings make up 8% of its $4.77B portfolio in Q4 2025.
  • Bridgeway Capital Management opened 101 new positions and closed 77 in Q4 2025.
  • Bridgeway Capital Management's portfolio value rose 1.8% quarter-over-quarter to $4.77B.

Based on Bridgeway Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.